Glecirasib shows ‘impressive’ activity in certain patients with pancreatic cancer

Glecirasib exhibited antitumor activity among patients with pancreatic ductal adenocarcinoma and other solid tumors harboring the KRAS G12C mutation variant, study findings presented at ASCO Gastrointestinal Cancers Symposium showed.
“Glecirasib monotherapy has demonstrated promising clinical activity in previously treated patients with KRAS G12C-mutated [pancreatic ductal adenocarcinoma] and other tumor types,” Jian Li, PhD, MD, a member of the department of gastrointestinal oncology at Peking University Cancer Hospital and Institute, said during a presentation. “Glecirasib

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart